Status:
RECRUITING
Contribution of PET/MRI in Locally Advanced Cervical Cancer (ATICC)
Lead Sponsor:
Institut de cancérologie Strasbourg Europe
Conditions:
Cervical Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
\[18 F\]fluorodeoxyglucose (18F-FDG) positron emission tomography-magnetic resonance imaging (PET/MRI) is a new hybrid imaging tool that has recently arrived in oncology, and is particularly promising...
Detailed Description
This monocentric, prospective trial aims at comparing performances of 18F-FDG PET/MRI versus standard PET/CT in the detection of lymph node metastases in cervical cancer patients. Specificity and sens...
Eligibility Criteria
Inclusion
- Patients aged from 18 years old and over
- Patients with presumed cervical cancer of stages IB2 to IVA based on clinical data and pelvic MRI, undergoing pre-treatment assessment.
- For women of childbearing potential : Adequate contraception throughout study participation.
- Note : enrollment in a concomitant clinical trial is authorized
Exclusion
- Oncological history that could possibly interfere with imaging results interpretation, apart from cervical cancer
- Extra-nodal metastasis clinically or radiologically proven before study participation
- Contraindication to MRI or injection of contrast agents containing gadolinium
- Contraindication to lumbo-aortic lymphadenectomy
- Persons deprived of liberty
- Minor or patients placed under guardianship or supervision
- Patient under judicial protection
- Patient unable to consent
Key Trial Info
Start Date :
October 12 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06083103
Start Date
October 12 2023
End Date
December 31 2025
Last Update
March 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut de cancérologie Strasbourg Europe
Strasbourg, France, 67033